AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
Where We Stand: AMCP opposes statutory and regulatory proposals that unduly restrict the ability of pharmacists working within managed care organizations from utilizing tools and services that are essential for the management of a prescription drug benefitFind out about Regulation of the Prescription Drug Benefit.
Where We Stand: AMCP supports off‐label use of FDA‐approved drugs when medically appropriate and necessary, but opposes government‐mandated coverage of specific pharmaceuticals, whether for FDA‐approved or off‐label uses.
Partnership Forum: Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. This forum helped identify potential structural issues within the current formulary and benefit design processes that may have led to racial health disparities or inequality.
Partnership Forum: This forum identified key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.
